<DOC>
	<DOCNO>NCT00344318</DOCNO>
	<brief_summary>This study evaluate safety , reactogenicity immunogenicity GSK Biologicals ' pneumococcal conjugate vaccine compare Prevenar™ co-administered DTPw-HBV/Hib OPV IPV vaccine , accord 2 different schedule : 6-10-14 week 2-4-6 month age . The study 2 group . - One group subject receive 3-dose primary vaccination GSK Biologicals ' pneumococcal conjugate vaccine ( three different lot use randomly allocate ) . - The 2nd group subject receive 3-dose primary vaccination Prevenar™ . All child receive concomitantly DTPw-HBV/Hib OPV IPV vaccine . This protocol post deal objective &amp; outcome measure primary study . The objective &amp; outcome measure Booster study present separate protocol posting ( NCT number =00547248 ) .</brief_summary>
	<brief_title>Safety Immunogenicity Study GlaxoSmithKline ( GSK ) Biologicals ' 10-valent Pneumococcal Conjugate Vaccine</brief_title>
	<detailed_description>The Protocol Posting update order comply FDA Amendment Act , Sep 2007</detailed_description>
	<mesh_term>Streptococcal Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<criteria>Male female , include , 612 week ( 42 90 day ) age time first vaccination . Subjects investigator believe parents/guardians comply requirement protocol Written inform consent obtain parent guardian subject . Free obvious health problem establish medical history clinical examination enter study . Born gestation period 36 42 week . Use investigational nonregistered product ( drug vaccine ) study vaccine ( ) within 30 day precede first dose study vaccine , plan use study period Chronic administration ( defined 14 day ) immunosuppressant immunemodifying drug within six month prior first vaccine dose . Planned administration/ administration vaccine foreseen study protocol period start one month dose vaccine ( ) end 7 day dose 1 dose 2 1 month dose 3 . Previous vaccination diphtheria , tetanus , pertussis , polio , hepatitis B , Haemophilus influenzae type b , and/or S. pneumoniae exception vaccine first dose give within first two week life accord national recommendation History intercurrent diphtheria , tetanus , pertussis , hepatitis B , polio , Haemophilus influenzae type b disease . History allergic disease reaction likely exacerbate component vaccine . History seizure ( criterion apply subject single , uncomplicated febrile convulsion past ) neurological disease . Acute disease time enrolment Any confirm suspected immunosuppressive immunodeficient condition base medical history physical A family history congenital hereditary immunodeficiency . Major congenital defect serious chronic illness . Administration immunoglobulins and/or blood product since birth plan administration active phase study .</criteria>
	<gender>All</gender>
	<minimum_age>6 Weeks</minimum_age>
	<maximum_age>12 Weeks</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Immunogenicity</keyword>
	<keyword>Safety</keyword>
	<keyword>Pneumococcal vaccine</keyword>
	<keyword>Pneumococcal disease</keyword>
</DOC>